Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Selected Balance Sheet Data

v3.21.1
Note 3 - Selected Balance Sheet Data
9 Months Ended
Mar. 31, 2021
Notes to Financial Statements  
Supplemental Balance Sheet Disclosures [Text Block]

Note 3. Selected Balance Sheet Data:

 

Inventories:

 

Inventories consist of (in thousands):

 

   

March 31,

   

June 30,

 
   

2021

   

2020

 

Raw materials

  $ 51,664     $ 51,530  

Finished goods(1)

    63,370       56,268  

Inventories, net

  $ 115,034     $ 107,798  

 

(1) Finished goods inventory of $5,044 and $4,646 included within other long-term assets in the respective March 31, 2021 and June 30, 2020, consolidated balance sheet. The inventory is included in long-term assets as it is forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.  

 

Property and Equipment:

 

Property and equipment consist of (in thousands):

 

    March 31,    

June 30,

 
    2021    

2020

 

Land

  $ 8,596     $ 8,516  

Buildings and improvements

    189,443       184,430  

Machinery and equipment

    187,855       153,704  

Property and equipment, cost

    385,894       346,650  

Accumulated depreciation and amortization

    (186,919

)

    (169,821

)

Property and equipment, net

  $ 198,975     $ 176,829  

 

Intangible Assets:

 

Intangible assets consist of (in thousands):

 

    March 31,    

June 30,

 
    2021    

2020

 

Developed technology

  $ 444,664     $ 434,653  

Trade names

    145,421       146,713  

Customer relationships

    219,575       211,750  

Patents and other intangibles(1)

    8,158       2,475  

Intangible assets

    817,818       795,591  

Accumulated amortization

    (328,640

)

    (279,046

)

Intangible assets, net

  $ 489,178     $ 516,545  

 

 

(1)

Increase in patents and other intangible assets is primarily due to $5.0 million recognized in intangible assets in the first quarter of fiscal 2021 for certain third party patented technology acquired. $4.0 million of the third party patented technology acquired was a non-cash activity within the condensed consolidated statement of cash flows as a cash payment was not made within the nine months ended March 31, 2021.

 

Changes to the carrying amount of net intangible assets for the quarter ended March 31, 2021 consist of (in thousands):

 

Beginning balance

  $ 516,545  

Acquisitions

    8,917  

Other additions

    5,750  

Amortization expense

    (46,237

)

Currency translation

    4,203  

Ending balance

  $ 489,178  

 

The estimated future amortization expense for intangible assets as of March 31, 2021 is as follows (in thousands):

 

2021 remainder

  $ 15,060  

2022

    59,539  

2023

    57,647  

2024

    55,016  

2025

    51,959  

Thereafter

    249,957  

Total

  $ 489,178  

 

Goodwill:

 

Changes to the carrying amount of goodwill for the quarter ended March 31, 2021 consist of (in thousands):

 

   

Protein Sciences

   

Diagnostics and

Genomics

   

Total

 

Beginning balance

  $ 373,081     $ 355,229     $ 728,310  

Acquisitions

    7,848       -       7,848  

Currency translation

    10,186       116       10,302  

Ending balance

  $ 391,115     $ 355,345     $ 746,460  

 

We evaluate the carrying value of goodwill in the fourth quarter of each fiscal year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. The Company performed a goodwill impairment assessment for all of its reporting units during the fourth quarter of fiscal 2020. No indicators of impairment were identified as part of our assessment. 

 

No triggering events were identified during the quarter ended March 31, 2021. There has been no impairment of goodwill since the adoption of Financial Accounting Standards Board (“FASB”) ASC 350 guidance for goodwill and other intangibles on July 1, 2002.